Efficacy of tirzepatide 5, 10 and 15 mg versus semaglutide 2 mg in patients with type 2 diabetes: An adjusted indirect treatment comparison-Reference-Cited by-同舟云学术

Efficacy of tirzepatide 5, 10 and 15 mg versus semaglutide 2 mg in patients with type 2 diabetes: An adjusted indirect treatment comparison

Published:2022-06-13 Issue:9 Volume:24 Page:1861-1868
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obesity Metabolism

Author:

Vadher Karan¹^ORCID,Patel Hiren²^ORCID,Mody Reema²,Levine Joshua A.²,Hoog Meredith²,Cheng Alice YY.³,Pantalone Kevin M.⁴^ORCID,Sapin Hélène⁵

Affiliation:

1. Eli Lilly and Company Bracknell UK

2. Eli Lilly and Company, Lilly Corporate Center Indianapolis Indiana

3. Division of Endocrinology and Metabolism, Department of Medicine, Trillium Health Partners and Unity Health Toronto University of Toronto Toronto Ontario Canada

4. Department of Endocrinology Cleveland Clinic Cleveland Ohio

5. Lilly France SAS Neuilly‐sur‐Seine France

Funder

Eli Lilly and Company

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.14775

Reference15 articles.

1. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial

2. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes

3. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial

4. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial

5. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. AT-7687, a novel GIPR peptide antagonist, combined with a GLP-1 agonist, leads to enhanced weight loss and metabolic improvements in cynomolgus monkeys;Molecular Metabolism;2024-10

2. Real‐world evaluation of the effects of tirzepatide in patients with type 2 diabetes mellitus;Diabetes, Obesity and Metabolism;2024-09-09

3. Tirzepatide and exercise training in obesity;Clinical Hemorheology and Microcirculation;2024-08-14

4. Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease?;Metabolism;2024-08

5. GLP1-GIP receptor co-agonists: a promising evolution in the treatment of type 2 diabetes;Acta Diabetologica;2024-06-03